Japan OKs Roche's Avastin for aggressive brain cancer

Roche has obtained approval from the Japanese Ministry of Health, Labour and Welfare to market Avastin, or bevacizumab, as a treatment for malignant glioma, including newly diagnosed glioblastoma, in combination with radiotherapy and temozolomide, and as a monotherapy for recurrent GBM and certain kinds of high-grade glioma. The approval makes Avastin the first globally approved drug for newly diagnosed glioblastoma.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX